In a groundbreaking development, the FDA has granted clearance to Osteoboost, a vibrating belt engineered by Bone Health Technologies, in collaboration with NASA, to enhance bone density in those battling osteopenia[1]. This nod marks a milestone, making Osteoboost the inaugural medical device of its kind approved for treating postmenopausal women.
A Vibrating Shield Against Osteoporosis
Osteoporosis, prevalent in half of postmenopausal women, poses a serious threat due to weakened, fracture-prone bones. Osteoboost aims to intercept this progression by mechanically fortifying hip and spine bones through gentle vibrations. Inspired by NASA’s zero-gravity research, this wearable tech emerges as a promising preventive measure.
Daily Rituals for Stronger Bones
For optimum efficacy, Osteoboost recommends a daily wear time of 30 minutes or at least five times a week. Its unobtrusive vibration feature allows flexible usage during daily activities like dog walks or dishwashing. Clinical trials, evidenced by CT scans, showcase visible improvement in bone density over time, with a minimal 0.5 percent loss in bone strength compared to the 3.4 percent in non-users.
Osteoboost in the Treatment Landscape
Existing preventative measures, primarily lifestyle changes, often face adherence challenges. Osteoboost bridges this gap, showing promise in mitigating bone density loss. Bone health expert emphasizes its potential significance in preserving bone strength.
Although Osteoboost is not yet available for purchase, enthusiasts can sign up for notifications. Scheduled for shipping later this year, the belt aims to be both “affordable and accessible.” Prescription-based acquisition may vary in cost, pending discussions with insurers. While price projections evolve, the potential debut at $800, as suggested by CEO Laura Yecies, underscores a commitment to accessibility.
